BIAL and Neurocrine Announce Exclusive North American Licensing Agreement for Opicapone
Opicapone approved in Europe in June 2016
Porto, Portugal and San Diego, California, February 10, 2017 - BIAL and Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that they have entered into an exclusive licensing agreement for the development and commercialization of opicapone in North America.
Opicapone is a once-daily, peripherally-acting, highly-selective catechol-O-methyltransferase inhibitor (COMT inhibitor) that was approved in June 2016 by the European Commission as an adjunct therapy to preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilized on those combinations.1
“We are pleased to have Neurocrine as our partner in developing and commercializing opicapone,” said António Portela, Chief Executive Officer of BIAL. “We believe this partnership is another landmark for BIAL”.